期刊文献+

MMP-2和EGFR在胃癌中的表达及其与生物学特征的关系 被引量:10

The Expression of MMP-2 and EGFR in the Tissues from Gastric Carcinoma
下载PDF
导出
摘要 目的探讨胃癌组织中EGFR与基质金属蛋白酶-2(MMP-2)的表达及其与胃癌生物学特征的关系。方法采用免疫组化方法检测64例胃癌原发灶标本中EGFR和MMP-2的表达,并观察其与胃癌生物学特征的关系以及EGFR与MMP-2表达的相关性。结果 64例胃癌组织中,EGFR和MMP-2的表达阳性率分别为31.3%(20/64)和68.8%(44/64);EGFR的过度表达与胃癌临床分期、有无淋巴结转移、TNM分期及组织分化程度相关(P<0.05);MMP-2的表达与胃癌临床分期、有无淋巴结转移及TNM分期亦相关(P<0.05),但与组织分化程度无明显相关(P>0.05);且EGFR的表达与MMP-2的表达存在相关性(P<0.05)。结论胃癌组织中EGFR的表达与MMP-2的表达密切相关,EGFR、MMP-2的表达水平可作为了解胃癌生物学行为和判断预后的指标。 Objective To evaluate the expression of EGFR and matrix metalloproteinase-2(MMP-2) in the tissues from gastric cancer and its relationship with the biological characteristics of gastric cancer.Methods The expression of EGFR and MMP-2 was detected by immunohistochemistry in the tissues from 64 patients with gastric cancer.Results The positive expression of EGFR and MMP-2 was 31.25%(20/64) and 68.75%(44/64);EGFR over-expression was related to the clinical stage,lymph node metastasis,TNM stage and the degree of differentiation(P〈0.05);MMP-2 over-expression was related to the clinical stage,lymph node metastasis and TNM stage(P〈0.05),but was not related to the degree of differentiation(P〉0.05);The expression of EGFR and MMP-2 was positively correlated(P〈0.05).Conclusion The expressions of EGFR and MMP-2 was correlated in the tissues from gastric cancer.
出处 《实用癌症杂志》 2010年第4期344-346,共3页 The Practical Journal of Cancer
关键词 胃癌 表皮生长因子受体 基质金属蛋白酶-2 生物学特征 Gastric cancer MMP-2 EGFR Biological characteristics
  • 相关文献

参考文献9

  • 1刘磊,白玉贤.EGFR靶向药物治疗胃肠道肿瘤的新进展[J].实用肿瘤学杂志,2008,22(4):382-384. 被引量:5
  • 2Schlessinger J,Ullrich A.Growth 2 factor signaling by receptor tyrosine kinase[J].Neuron,1992,28(9):383.
  • 3Rajkumar T.Growth factors and growth factor receptors in cancer (Review)[J].Curr Sci,2001,81 (5):535.
  • 4Yamazaki H,Kijima H,Ohnishi Y,et al.Inhibition of tumor growth by ribozyme mediated suppression of aberrant epidermal growth factor receptor gene expression[J].J Natl Cancer Inst,1998,90(6):581.
  • 5Del Rosso M,Fibbi G,Pucci M,et al.Multiple pathways of cell invasion are regulated by multiple families of serine proteas[J].Clin Exp Metastasis,2002,19(3):193.
  • 6Kleiner DE,Stetler,Stevenson WG.Matrix metallop roteinases and metastasis[J].Cancer Chemother Pharmacol,1999,43 (supp l):S42.
  • 7Parsons SL,Watson SA,Collins HM,et al.Gelatinase (MMP2 and MMP9) expression in gastrointestinal malignancy[J].Br J Cancer,1998,78 (11):1495.
  • 8Monig SP,Baldus SE,Hennecken JK,et al.Expression o-f MMP-2 is associated with progression and lymph nodemetastasis of gastric carcinoma[J].Histopathology,2001,39(6):597.
  • 9Manman Gong,Lin Meng,Beihai Jiang,et al.P37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR[J].Mol Cancer Ther,2008,7(3):530.

二级参考文献21

  • 1李中信,于跃明.中低位进展期直肠癌治疗现状及发展趋势[J].实用肿瘤杂志,2007,22(3):203-205. 被引量:2
  • 2胡雪君,宋娜,刘云鹏,马艳菊,郝艳艳,康健.EGFR、VEGF和COX-2在非小细胞肺癌中的表达和意义[J].实用肿瘤杂志,2007,22(3):209-213. 被引量:19
  • 3Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factbr receptor[J]. J Clin Oncol, 2004,22 :1201-1208
  • 4Lenz H J, Mayer RJ, Gold PJ, et al. ActiVely of Cetuximab in patients with colorectal cancer refractory to both Irinotecan and Oxaliplatin[J]. J Clin Oncol, 2004,24:3510
  • 5Veronese ML , O'Dwyer PJ . Monoclonal antibodies in the treatment of colorectal cancer[J] . Eur J Cancer , 2004 ,40(9) :1292-1301
  • 6Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J].J Clin Oncol, 2003,21(14):2787-2799
  • 7ShahMA, Ilson D, Ramanathan RK, et al. A Multicenter Phase Ⅱ study of Irinotecan (CPT) , Cisp latin (CIS) , and Bevacizumab (BEV) in pa:tients with unresectable ormetastatic gastric or gas2 troesophageal junction ( GEJ ) adenocarcinoma I[J]. Proc Am Soc Clin Oncol, 2005, 24:4025
  • 8Campiglio M, Locatelli A, Olgiati C, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level[J]. J Cell Physiol, 2004,198 (2) :259-268
  • 9Burtness B. The role of cetuximab in the treatment of squamous cell of head and neck [J]. Expert Op in Bio Ther, 2005, 5 ( 8 ) : 1085 - 1093
  • 10Huether A, Hopfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer[J]. Biochem Pharmacol, 2005, 70(11):1568-1578

共引文献4

同被引文献105

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部